Passed Sat, 22 Aug 2026 CAPR Capricor Therapeutics, Inc. FDA action or review extension for Capricor's Deramiocel is due after a 3 to 9 negative panel vote 6.29 10% to 25% in either direction on a normal extension, a 35% to 55% decline on a rejection, and a gain above 100% on a surprise approval. +44.67% High +0.79% Low Details for CAPR CAPR result After the event it went to +44.67% at its highest, and later to +0.79% at its lowest, against the close price before FDA extension.
The news was
The FDA accepted the amendment, which is the good half, and pushed the decision back three months to 22 November, which is the bad one.
Measured from Price at analysis Close price before FDA extension Detailed view The FDA accepted a major amendment to Capricor’s Deramiocel approval application and extended the review; the decision is now due November 22, 2026.
CAPR price from the signal through FDA extension, in the order it happened. Price Date and time 9.66 6.07 16:34 18:39 20:00 13:03 13:25 13:30 13:46 20:00 21 Aug 24 Aug 28 Aug After signal After FDA extension (24 Aug 2026, 13:25 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Fri, 11 Sept 2026, 22:25 SRRK Scholar Rock Holding Corporation FDA approves Scholar Rock's apitegromab as Isembyld, unlocking its first commercial drug launch 55.41 +8% to +15% +26.06% High −7.96% Low Details for SRRK SRRK result After the event it went to +26.06% at its highest, and later to −7.96% at its lowest, against the close price before FDA decision.
The news was
Approval gives Scholar Rock its first product, with a broad label, a $310,000 annual price and a priority review voucher. Against that, the fracture warning had not been disclosed before, management wrongly told investors on the Sunday call that there were no post-marketing safety requirements, and with the binary risk gone the stock traded as a launch story that has not started yet.
Measured from Price at analysis Close price before FDA decision Detailed view The FDA approved apitegromab as ISEMBYLD after the close on 11 September 2026, 19 days before the deadline, with a broad label and a fracture warning. The stock jumped after hours, then closed the first session 6.42% lower and kept falling for a week.
What else moved the price
Most of the fall was stock-specific. On 14 September SRRK fell 6.42% while XBI rose 0.90%. On 15 September the company filed an 8-K correcting its Sunday call, confirming a pregnancy safety study and 15-day fracture reporting, and Barclays downgraded it to Equalweight while raising its target to $58 from $55. XBI fell 2.27% that day, which accounts for part of the 3.57% drop. Before the decision the stock had drifted down from the signal price with no apitegromab news, to a $53.86 low on 10 September.
SRRK price from the signal through FDA decision, in the order it happened. Price Date and time 69.85 48.63 55.41 20:00 22:45 22:50 13:30 19:41 20:00 23:26 31 Aug 2 Sept 10 Sept 11 Sept 14 Sept 25 Sept After signal After FDA decision (11 Sep 2026, 22:25 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Tue, 8 Sept 2026, 16:30 IonQ Investor Day could reset combined-company guidance and the quantum roadmap 39.52 +7% to +12% +12.42% High −0.18% Low Details for IONQ IonQ held its Investor Day and issued its first combined 2026 revenue outlook of $450 million to $460 million, plus roadmap updates. This sets the first view of the IonQ and SkyWater plan, like a family sharing its first joint budget, but no near-term profit or margin targets were given, so timing on profitability will need a future update.
IONQ price from the signal through investor day, in the order it happened. Price Date and time 44.86 36.78 39.52 20:00 12:47 13:30 13:36 18:15 20:00 21 Aug 24 Aug 2 Sept 4 Sept 8 Sept 9 Sept After signal After investor day (08 Sep 2026, 12:47 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Tue, 8 Sept 2026, 11:00 BEAM Beam Therapeutics Inc. Beam Therapeutics presents updated BEAM-302 clinical data at the European Respiratory Society Congress 29.66 +8% to +15% +9.91% High −15.58% Low Details for BEAM Beam reported updated BEAM-302 results showing higher levels of the healthy AAT protein and no major new safety issues. The company is pursuing a faster approval path based on a lab test, for example if the right test number goes up you can ask for a quicker review, but a regulator still has to decide.
BEAM price from the signal through clinical data, in the order it happened. Price Date and time 32.65 25.04 29.66 10:03 10:37 13:30 13:48 20:00 21 Aug 25 Aug 26 Aug 3 Sept 4 Sept 8 Sept 9 Sept After signal After clinical data (8 Sep 2026, 10:00 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Fri, 11 Sept 2026 TLX Telix Pharmaceuticals Limited FDA decision on resubmitted Pixclara application could reset Telix growth expectations 11.29 — +9.12% High +0.97% Low Details for TLX The FDA approved Pixclara on 14 September, three days after the target action date. The stock reached 12.32 before the market opened and fell for the rest of the day, closing at 11.78, up 4.34% on the session and less than half the move the card expected from an approval.
TLX price from the signal through FDA decision on the resubmitted Pixclara New Drug Application, in the order it happened. Price Date and time 12.50 10.80 11.29 18:05 20:05 12:00 12:02 13:30 13:47 20:00 21:21 21 Aug 1 Sept 9 Sept 11 Sept 14 Sept 15 Sept After signal After FDA decision on the resubmitted Pixclara New Drug Application (2026-09-14) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Thu, 10 Sept 2026, 12:00 Macy's second-quarter results will test whether its turnaround can support another guidance increase 21.51 +4% to +9% +7.58% High −8.09% Low Details for M M result After the event it went to +7.58% at its highest, and later to −8.09% at its lowest, against the close price before earnings.
The news was
Sales, comparable sales and profit all beat and the full year was raised. Against that, $0.23 of the $0.63 came from a tariff refund, and the third quarter was guided to a loss with comparable sales around flat.
Measured from Price at analysis Close price before earnings Detailed view Macy's beat on sales and profit, grew comparable sales for a fifth straight quarter and raised its full-year outlook, helped by a $116 million tariff refund. It then guided to a third-quarter adjusted loss with comparable sales around flat, and the shares fell.
M price from the signal through earnings, in the order it happened. Price Date and time 23.38 19.77 21.51 19:58 20:00 10:44 10:55 13:30 13:31 13:44 20:00 25 Aug 8 Sept 9 Sept 10 Sept 11 Sept After signal After earnings (10 Sep 2026, 10:55 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Tue, 15 Sept 2026 ROLR High Roller Technologies, Inc. High Roller Technologies launches the invitation-only ROLR prediction markets platform on September 15 6.36 +6% to +15% +7.55% High −1.26% Low Details for ROLR High Roller Technologies launched the invitation-only beta of its ROLR prediction markets platform on schedule, and said the full commercial launch is still on track for the end of October. It published no user numbers and did not say whether real-money trading is live, so the market took the headline and little else.
ROLR price from the signal through product launch, in the order it happened. Price Date and time 6.84 5.93 6.36 19:05 20:00 20:01 12:12 12:19 13:30 13:36 13:48 20:00 3 Sept 4 Sept 14 Sept 15 Sept After signal After product launch (15 Sep 2026, 12:12 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Tue, 25 Aug 2026 FDA decision on Ziihera first-line gastric cancer expansion could unlock $250 million for Zymeworks 28.77 7% to 15% gain on clean approval. +6.01% High −10.98% Low Details for ZYME The FDA approved Ziihera with chemotherapy, with or without tislelizumab, for first-line treatment of certain stomach and esophageal junction cancers. The approval triggers a $250 million milestone payment to Zymeworks from Jazz.
ZYME price from the signal through FDA approval, in the order it happened. Price Date and time 31.00 25.61 28.77 20:00 09:05 20:00 13:39 14:00 14:39 17:54 20:00 20 Aug 24 Aug 25 Aug 30 Aug After signal After FDA approval (25 Aug 2026, 14:00 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Wed, 16 Sept 2026, 23:00 Snap SPECS augmented reality glasses launch and first in-depth demonstration 5.72 +8% to +15% on a strong launch, -10% to -18% on a weak launch +5.59% High −1.57% Low Details for SNAP SNAP result After the event it went to +5.59% at its highest, and later to −1.57% at its lowest, against the close price before product launch.
The news was
On one side the product worked in public and arrived with a serious partner list, spanning enterprise software at Salesforce and AWS, retail at Shopify, sport at the NBA and WNBA, connectivity at Verizon and AI agents at Nvidia, which is the platform case the company needed to make. On the other, the three things that would turn a platform into revenue were all absent: no shipping date, no preorder numbers and no cheaper model, with the price still $2,195.
Measured from Price at analysis Close price before product launch Detailed view Snap gave the first full demonstration of its $2,195 Specs, showing an AI assistant, hand-tracking control with no wristband, and partner work with Verizon, Shopify, Salesforce, AWS, Nvidia, the NBA and WNBA and HBO, and opened a hands-on space in Los Angeles from 1 October. It gave no shipping date, no preorder numbers and no cheaper model, and the shares gave back an early gain.
What else moved the price
The card called the day crowded and named the Federal Reserve, and the crowding was real but it helped rather than hurt. The decision landed on 16 September, hours before the keynote, so it sat behind the launch rather than competing with it, and on 17 September the comparison stocks all rose: Qualcomm 2.09%, Apple 1.38%, Meta 1.34% and Alphabet 1.30%. Snap falling into a technology tape that was up made the reaction easier to attribute to the launch, not harder. Quarterly index expiry on 18 September, which the card also flagged, falls outside the window measured here.
SNAP price from the signal through product launch, in the order it happened. Price Date and time 6.07 5.17 5.72 20:00 23:01 13:30 16:02 19:59 20:00 21 Aug 24 Aug 15 Sept 16 Sept 17 Sept After signal After product launch (16 Sep 2026, 23:00 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Sat, 19 Sept 2026 RARE Ultragenyx Pharmaceutical Inc. FDA decision on UX111 could restore part of Ultragenyx's lost pipeline value 12.88 +12% to +25% +4.43% Low +17.39% High Details for RARE The FDA approved UX111 as FAYUVI on 17 September 2026, two days before its target date and as a standard full approval rather than the accelerated approval the application sought. It is the first treatment ever approved for Sanfilippo syndrome type A, it cleared the manufacturing objection that caused the 2025 rejection, and it came with a priority review voucher. The stock rose 12.58% on the day.
What else moved the price
About a third of the day was not this decision. The stock opened 17 September at $13.22 and had already climbed to $13.50 before the tape broke at 18:28 UTC, a gain of 4.81% on no company news, on a day the biotechnology ETF XBI closed 2.64% higher and SPY 1.13% higher. The approval itself is the move from $13.50 to the $14.50 close, 7.41%. Nothing else lands in the window: the card called the day clear and it was, with the Federal Reserve decision the day before and the monthly options expiration the day after, both outside it. Worth separating from the result is what has happened since. The stock is at $16.04 as this is written on 22 September, 12.09% above the signal price and well beyond anything the approval session produced, which is a repricing of the two priority review vouchers and the launch rather than a reaction to the decision.
RARE price from the signal through FDA decision, in the order it happened. Price Date and time 16.04 12.73 19:25 20:00 18:28 18:34 19:59 20:00 20:23 10 Sept 11 Sept 16 Sept 17 Sept 22 Sept After signal After FDA decision (17 Sep 2026, 18:28 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Wed, 2 Sept 2026, 21:00 Broadcom fiscal third-quarter results and AI revenue outlook 367.24 6% to 10% gain lasting one to five sessions. +3.39% High −6.78% Low Details for AVGO Broadcom reported quarterly results with revenue of $29.591B and $16.7B from AI chips, more than half of its sales. It raised its outlook for the next quarter to about $34.8B in revenue.
AVGO price from the signal through earnings, in the order it happened. Price Date and time 379.69 342.20 367.24 20:00 20:18 20:27 21:24 13:30 14:47 19:47 20:00 21 Aug 26 Aug 28 Aug 2 Sept 3 Sept 4 Sept After signal After earnings (02 Sep 2026, 20:26 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Fri, 25 Sept 2026, 01:00 Tesla launches high-volume Semi production at its new Nevada truck factory, a week before the Roadster reveal 377.94 +1% to +3% if Tesla gives a production rate, price and fleet orders, -1% to -3% if it is a tour with no numbers +2.35% High −2.72% Low Details for TSLA Tesla delivered a real but partial positive: named fleet customers at a completed, running factory, without an official price or a dated production number. The stock opened into the card's positive range, up as much as 2.09%, before giving it all back and closing down 1.79% from the signal price, on Tesla-specific analyst target cuts and a European regulatory delay unrelated to the Semi event, while the S&P 500 rose 0.51% the same session.
What else moved the price
The card named PACCAR, Cummins and Rivian as the comparisons and the Roadster reveal and delivery count a week later as the events that would matter more. Neither shows up as the explanation here; the reversal is attributed specifically to Tesla-level analyst and regulatory news rather than to sector or peer moves.
TSLA price from the signal through Semi high-volume production launch, in the order it happened. Price Date and time 386.83 367.67 377.94 09:44 16:13 20:00 08:00 13:30 13:31 14:43 20:00 22 Sept 23 Sept 24 Sept 25 Sept After signal After Semi high-volume production launch (25 Sep 2026, 01:00 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Wed, 9 Sept 2026, 13:30 Backblaze Investor Day will set the AI growth and long-term financial framework 13.89 +6% to +12% +2.16% High −6.12% Low Details for BLZE BLZE result After the event it went to +2.16% at its highest, and later to −6.12% at its lowest, against the close price before investor day.
The news was
Storage growth was guided above 40% with about $396 million of customer commitments behind it. Against that, management said gross margin will fall while it builds the capacity, gave no cash flow target, and had raised $201 million of convertible notes to pay for it.
Measured from Price at analysis Close price before investor day Detailed view Backblaze held its first Investor Day and guided B2 Cloud Storage revenue growth above 40% through 2027, with multi-year customer commitments of about $396 million behind it. Management also said gross margin will dip while it builds the capacity those contracts need, and set no free cash flow target after raising $201 million of convertible notes.
BLZE price from the signal through investor day, in the order it happened. Price Date and time 16.11 12.54 13.89 13:30 13:47 19:43 20:00 21 Aug 24 Aug 3 Sept 8 Sept 9 Sept 10 Sept After signal After investor day (9 Sep 2026, 13:30 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Thu, 17 Sept 2026, 15:00 Intuit Investor Day could reset AI growth targets after a 48% one-year stock decline 318.13 +4% to +8% +1.80% High −1.74% Low Details for INTU INTU result After the event it went to +1.80% at its highest, and later to −1.74% at its lowest, against the close price before investor day.
The news was
The numbers were held and the customer base was not. On the good side, fiscal 2027 was reaffirmed at $23,279 million to $23,512 million with GAAP earnings per share of $20.12 to $20.36, the first quarter was guided to 11% revenue growth and 30% to 33% non-GAAP earnings growth, mid-market revenue grew 39% on 28% customer growth, Intuit Enterprise Suite reached nearly $150 million of annualised revenue at four times the prior year, and Credit Karma was guided to 11% to 13% growth. On the bad side, Intuit disclosed that it had missed new-customer targets in do-it-yourself tax and QuickBooks Online, lost a point of IRS e-file share in fiscal 2026, guided TurboTax to 2% to 3% and Mailchimp to down 1% to flat, named price as the main reason customers leave, and raised none of its long-term targets.
Measured from Price at analysis Close price before investor day Detailed view Intuit reaffirmed its fiscal 2027 guidance to the dollar, left its three-year growth bands where they already were at 10% to 15% for the business platform and 4% to 8% for consumer, and told investors it had missed its own new-customer targets in do-it-yourself tax and QuickBooks Online, with chief executive Sasan Goodarzi saying the number one reason customers left was price. The stock rose to $323.86 in the first thirty-nine minutes of the presentation, gave all of it back within the hour and closed 1.57% lower at $313.13 on a day the Nasdaq Composite rose 1.69%.
What else moved the price
The card called the day crowded and it was, but not in the way it expected. Its own read was that a beaten-down software name would trade the Federal Reserve rather than its targets, and that the honest measure was the 17 September close against the Nasdaq. The Nasdaq Composite rose 1.69% to 26,418.30 that day, recovering Wednesday’s post-Fed selloff, so duration was a tailwind and Intuit still fell 1.57%. A second move was running underneath it: the three software peers the card named all fell harder than Intuit did, with Salesforce down 3.07%, BILL 2.92% and HubSpot 2.91%, while ServiceNow fell 0.97%, Paycom 0.67% and the IGV software ETF rose 0.78%. So a sell-off in application software was working against the stock on the day, and Intuit outperformed the cohort the card itself picked. The following session was quarterly index expiry, which the card told readers to discount, and Intuit fell another 3.17% on 2.4 times its recent average volume.
INTU price from the signal through investor day, in the order it happened. Price Date and time 363.70 303.19 318.13 15:00 15:39 16:37 20:00 2 Sept 3 Sept 10 Sept 16 Sept 17 Sept 18 Sept After signal After investor day (17 Sep 2026, 15:00 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Thu, 1 Oct 2026, 12:00 Accenture gives its first fiscal 2027 guidance after the worst single day in its history 183.37 -8% to -15% if bookings miss again or growth is guided below 3% +1.71% Low +24.14% High Details for ACN Accenture reported fiscal fourth quarter 2026 results at 10:39 UTC on 1 October, before the US open. New bookings were $22.2 billion against the $20 billion the card set as the upward threshold, revenue of $18.68 billion came in above the company's own guided range, and fiscal 2027 revenue growth was guided to 3% to 6% in local currency. The stock rose 15.78% to $212.30, its largest one-day gain in the two years of daily bars the feed carries, against a card that expected a fall.
What else moved the price
This was Accenture's own news almost entirely. The S and P 500 tracking fund rose 0.18% on 1 October and the technology sector fund 1.05%, against Accenture's 15.78%, and the largest peer move was Wipro at 6.67%, less than half of it. The crowded morning the card warned about did not interfere. Jobless claims at 12:30 UTC left no mark on the tape, and the stock made its high of $227.63 twelve minutes after the 14:00 UTC ISM survey before fading through the afternoon to close at $212.30. The move the card did not see coming was the one before the event, not the one on the day. The stock fell 3.64% from the $190.29 signal price to the $183.37 pre-news close with no company news to account for it, including a 4.73% fall on 18 September to $181.29 on 11,664,716 shares against 2,936,047 the session before. That was the September quarterly expiry, which is the likeliest explanation for the volume, and no Accenture news was published that day. One consequence matters for reading the percentages: measured from the pre-news close the reaction is 15.78%, and measured from the card's own signal price it is 11.57%, because the stock had already given back part of its summer recovery before the release.
ACN price from the signal through fiscal fourth quarter results, in the order it happened. Price Date and time 227.63 172.11 183.37 10:39 13:30 14:12 19:57 20:00 17 Sept 18 Sept 21 Sept 29 Sept 30 Sept 1 Oct After signal After fiscal fourth quarter results (1 Oct 2026, 10:39 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Thu, 1 Oct 2026, 20:15 NIKE’s fiscal Q1 results could trigger a relief rally if margins and guidance finally turn 35.15 +6% to +11% +1.59% High −10.90% Low Details for NKE NIKE reported fiscal first quarter revenue of $11.213 billion, below market expectations, while diluted earnings of $0.48 beat and gross margin expanded 60 basis points to 42.8%. The company then guided fiscal 2027 revenue down high-single digits and adjusted earnings to $1.15 to $1.35. The shares closed 2 October at $33.87, down 3.64% from the pre-news close and 9.32% from the card's signal price.
What else moved the price
The first after-hours fall was NIKE's own news. The next regular session had a meaningful favorable outside driver: the September employment report showed only 29,000 net jobs added, cooling inflation concerns, and the S and P 500 rose 0.7% while NIKE recovered from its $32.55 open and $31.97 low to close at $33.87. That broad rally reduced the closing loss rather than causing it. The peer tape was mixed, with DECK down 0.57%, LULU down 1.46% and UAA up 1.51%, so there was no sector move large enough to explain NIKE's fall.
NKE price from the signal through fiscal first quarter earnings, in the order it happened. Price Date and time 37.47 31.32 35.15 19:59 20:00 20:15 10:44 13:30 13:32 19:59 20:00 9 Sept 10 Sept 14 Sept 1 Oct 2 Oct After signal After fiscal first quarter earnings (1 Oct 2026, 20:15 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Thu, 27 Aug 2026 GILD Gilead Sciences, Inc. FDA decision for Gilead’s once daily HIV pill BIC/LEN, PDUFA date August 27, 2026 148.86 — +0.48% High −2.72% Low Details for GILD The FDA approved Bixlenvo, Gilead’s HIV treatment that combines bictegravir and lenacapavir, for adults whose virus is already suppressed on treatment. The decision clears the way for a US launch.
GILD price from the signal through FDA approval, in the order it happened. Price Date and time 149.62 142.95 148.86 17:36 19:57 20:46 20:00 21:54 13:30 19:06 20:00 20:28 20 Aug 26 Aug 27 Aug 28 Aug 31 Aug After signal After FDA approval (27 Aug 2026, 21:47 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Thu, 1 Oct 2026 Snap prepares public Specs demos in Los Angeles as its site and Westfield list different opening dates 5.40 +2% to +5% if reviews are strong and a shipping date is named, -2% to -5% if early users find Specs heavy and limited +0.37% Low +6.11% High Details for SNAP SNAP result After the event it went to +0.37% at its lowest, and later to +6.11% at its highest, against the close price before Specs public demos open.
The news was
The product feedback was positive on display quality, comfort and spatial interaction, but the $2,195 price, conspicuous frame and first-generation limitations remain. Most importantly for the stock, Snap disclosed no shipment date or demand number that could change revenue expectations.
Measured from Price at analysis Close price before Specs public demos open Detailed view Snap put Specs in front of the public at Westfield Century City, though Snap's October 1 availability language and Westfield's October 2 operating calendar disagree by a day. Hands-on impressions were encouraging but brought no firm shipping date, order volume or enterprise order, leaving the event as product validation rather than a financial catalyst.
What else moved the price
The percentage depends heavily on the baseline. SNAP had fallen to $5.40 before the event, 3.91% below the $5.62 card price, and then closed 1 October at $5.65. That is a 4.63% day rise but only a 0.53% gain from the signal, so ordinary volatility and recovery from the pre-event decline explain more than the demo itself.
SNAP price from the signal through Specs public demos open, in the order it happened. Price Date and time 5.75 5.08 5.40 14:06 20:00 18:00 18:06 19:59 20:00 23:15 22 Sept 23 Sept 24 Sept 29 Sept 30 Sept 1 Oct After signal After Specs public demos open (1 Oct 2026, 14:00 ET (18:00 UTC)) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Tue, 25 Aug 2026 JAZZ Jazz Pharmaceuticals plc FDA decision on Ziihera combinations could open the first-line HER2-positive gastroesophageal cancer market 254.47 4% to 8% on a broad approval. +0.27% Low +4.68% High Details for JAZZ The FDA approved Ziihera for first-line treatment of a form of stomach and esophageal cancer, for use with an immunotherapy plus chemotherapy and also with chemotherapy alone. This enables a U.S. launch in both options, with the chemo-only use limited to a narrower group.
JAZZ price from the signal through FDA approval, in the order it happened. Price Date and time 266.38 247.11 254.47 14:46 20:00 20:59 13:40 14:00 15:05 20:00 21 Aug 24 Aug 25 Aug 28 Aug After signal After FDA approval (25 Aug 2026, 14:00 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Fri, 25 Sept 2026, 19:00 MIRM Mirum Pharmaceuticals, Inc. FDA approves Atebrioz for FOP, adding Mirum's fourth commercial medicine 89.36 +8% to +15% −0.40% Low +2.95% High Details for MIRM The FDA approved Atebrioz exactly as scheduled, but the stock had already fallen about 8% from the card's signal price by the day before the decision, on an unrelated pipeline setback in volixibat that the card did not flag as a near-term risk. The approval itself produced only a modest bounce, from an $89.36 pre-announcement close to a $92.00 extended-hours high, roughly 3%, well short of the 8% to 15% the card modeled for the event on its own.
What else moved the price
The card named competition from Regeneron's Pasatru and Ipsen's Sohonos and possible short covering as factors that could shape the size of the reaction. Neither shows up clearly in the muted move; the unrelated volixibat setback looks like the larger force acting on the stock in this window.
MIRM price from the signal through FDA approval of Atebrioz for FOP, in the order it happened. Price Date and time 103.28 87.64 89.36 15:43 20:00 19:00 19:54 20:00 23:09 31 Aug 11 Sept 24 Sept 25 Sept After signal After FDA approval of Atebrioz for FOP (25 Sep 2026, 19:00 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Tue, 29 Sept 2026 CCL Carnival Corporation & plc Carnival beats its third quarter guidance and lifts the full-year figure despite a higher fuel assumption 22.14 +5% to +10% if the full-year guidance of about $2.22 is held or raised, -5% to -9% if fuel forces another cut −0.68% Low +14.23% High Details for CCL Carnival reported fiscal third quarter adjusted earnings of $1.43 against the $1.35 it had guided, lifted its full-year figure to about $2.24 from about $2.22 instead of cutting it for a third time, and said 2027 is half booked at record occupancy and pricing. The shares rose 13.41% on 29 September 2026 to $25.11, the largest results-day move in two years, and have kept almost all of it.
What else moved the price
Almost nothing else was in this move. On 29 September the S&P 500 tracker SPY fell 0.18% and the consumer discretionary tracker XLY rose 0.14%, so a 13.41% day was the company alone. Two outside things did help at the margin. Oil fell hard on the same session, with the Brent tracker BNO down 2.62% and the broader oil tracker USO down 4.44%, which is a direct relief on the one input cost this card was built around. And the Conference Board consumer confidence index landing at a twelve-year low of 81.9 was the risk the card named most clearly, and it simply did not register. The two sessions after were the mirror image: BNO rose 2.28% on 30 September and 4.76% on 1 October, and Carnival gave back 2.27% into quarter end on 30 September before recovering 2.16% on 1 October. Worth noting from the pre-event window too: the stock made a failed rally to $23.35 intraday on 22 September on 40,626,431 shares and still closed that day at $22.28, then set its low of $21.45 on 24 September, so the selling the card described was still running right up to the print.
CCL price from the signal through third quarter results, in the order it happened. Price Date and time 25.29 21.45 22.14 13:15 13:30 18:41 20:00 18 Sept 22 Sept 24 Sept 28 Sept 29 Sept After signal After third quarter results (29 Sep 2026, 13:15 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Thu, 27 Aug 2026, 21:00 AFRM Affirm Holdings, Inc. Affirm fiscal Q4 2026 results and fiscal 2027 outlook could reset growth expectations 77.49 +12% to +18% on strong guidance, -10% to -16% on weak guidance −0.77% Low +16.71% High Details for AFRM AFRM result After the event it went to −0.77% at its lowest, and later to +16.71% at its highest, against the close price before earnings.
The news was
Revenue, volume and operating margin all came in above the card’s range. Against that, the 2027 volume guide implies growth below the 25% a lasting rally needed.
Measured from Price at analysis Close price before earnings Detailed view Affirm reported fourth-quarter results, posting $1.185B in revenue, $14.1B in gross merchandise volume and about a 12.5% GAAP operating margin. It guided fiscal 2027 to more than $60B in GMV with adjusted operating margin above 30%, and said reported net income was lifted by a non-cash tax allowance release.
AFRM price from the signal through earnings, in the order it happened. Price Date and time 90.44 73.44 77.49 19:46 20:00 20:02 20:20 20:32 20:34 13:30 19:59 20:00 21 Aug 24 Aug 27 Aug 28 Aug 31 Aug After signal After earnings (27 Aug 2026, 20:32 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Mon, 21 Sept 2026 FDA decision on Merck’s Winrevair HYPERION label update for recently diagnosed pulmonary arterial hypertension 149.50 +0.5% to +2.0% −0.98% Low +2.72% High Details for MRK The FDA approved the Winrevair label update adding HYPERION data for adults newly diagnosed with pulmonary arterial hypertension, and Merck announced it before the open on 22 September 2026, the morning after the target date. The stock rose 0.94% on the day and gave it back the next.
What else moved the price
The card rated the day clear and it was: 22 September carried no market-moving data, and the S&P 500 ETF SPY closed 0.02% lower. The healthcare sector did help. XLV rose 0.52%, a little over half of Merck's 0.94%, so the approval itself accounts for less than half a percent. One unexplained print: at 14:57 ET a single minute traded 1.24 million shares at about $151.70, more than a tenth of the day's volume, with no news found to match it. The bigger moves in this window were not the decision at all. The stock fell from $152.55 to $143.79 between publication and 15 September with no Winrevair news, and rose 1.79% on 21 September with the whole market, SPY up 1.55%.
MRK price from the signal through FDA label update, in the order it happened. Price Date and time 157.00 142.25 149.50 19:55 20:00 13:49 20:02 10:45 13:30 13:40 15:24 20:00 21 Aug 25 Aug 15 Sept 21 Sept 22 Sept 23 Sept After signal After FDA label update (22 Sep 2026, 10:45 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Tue, 22 Sept 2026 AutoZone reports fourth quarter results with the stock at a two-year low after three straight results-day falls 2803.25 +5% to +10% if domestic same-store sales are at or above 3.7% and earnings clear $54.22, -6% to -12% if same-store sales land near the 2.5% UBS expects −1.01% Low +6.99% High Details for AZO AZO result After the event it went to −1.01% at its lowest, and later to +6.99% at its highest, against the close price before Earnings.
The news was
Earnings beat and gross margin rose 182 basis points, but a $96 million tariff refund worth $4.43 a share did the work; without it earnings missed. Domestic same-store sales of 1.6% were the weakest in the series, with the do-it-yourself business down 0.6%, while commercial sales grew 8.6%. The outlook for fiscal 2027 calls for flat to low-single-digit domestic same-store sales and a much smaller inventory accounting charge.
Measured from Price at analysis Close price before Earnings Detailed view AutoZone reported fourth quarter earnings of $56.05 a share, above the $54.22 expected, on domestic same-store sales of 1.6%, well below the 3.7% the market wanted. The earnings beat came from a $96 million tariff refund. The stock still rose 3.26%, along with the rest of the auto parts group.
What else moved the price
The card rated the day clear, and the macro calendar was: SPY closed down 0.02%. But the auto parts group rose together. O'Reilly gained 3.55%, Advance Auto Parts 4.02% and Genuine Parts 2.48%, close to or above AutoZone's 3.26%, so part of the day reads as a sector move, whether as relief that AutoZone's commercial business and margin held up or for reasons of its own. Nothing else specific to O'Reilly was found for that day. The sharpest swing came during the call, from $2,999.30 at 10:06 ET to $2,844.80 at 10:12 ET, minutes after the Richmond Fed survey the card had flagged for that time, and no cause for it was found. Before the report the stock fell 1.82% on 21 September to a new low, so the results day started from further down than the card was written at.
AZO price from the signal through Earnings, in the order it happened. Price Date and time 2999.30 2775.00 2803.25 13:30 19:57 20:00 10:24 10:55 11:00 13:30 14:06 14:12 20:00 18 Sept 21 Sept 22 Sept 23 Sept After signal After Earnings (22 Sep 2026, 10:55 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Thu, 10 Sept 2026, 17:00 Omada Health holds its first Investor Day and presents long-term growth plans 21.50 +4% to +8% −1.40% Low +6.00% High Details for OMDA OMDA result After the event it went to −1.40% at its lowest, and later to +6.00% at its highest, against the close price before investor day.
The news was
The margin target came in at 30%, double what was expected. Against that, the revenue growth target of at least 20% is a planned slowdown from the 43% the company is running at.
Measured from Price at analysis Close price before investor day Detailed view Omada Health used its first investor day to set long-term targets of at least 20% annual revenue growth, an 80% non-GAAP gross margin and a 30% adjusted EBITDA margin. The growth target is slower than the pace the company is running at now, and the shares ended the day unchanged before falling the next session.
OMDA price from the signal through investor day, in the order it happened. Price Date and time 25.60 19.66 21.50 17:57 20:00 13:00 13:30 14:20 20:00 21 Aug 26 Aug 27 Aug 9 Sept 10 Sept 11 Sept After signal After investor day (10 Sep 2026, 13:00 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Thu, 24 Sept 2026 COST Costco Wholesale Corporation Costco reports fiscal fourth quarter results after a year of beating and still falling 896.48 +3% to +6% if revenue clears $94.85 billion and renewal holds, -3% to -6% if revenue misses $94 billion or renewal slips −1.49% Low +3.20% High Details for COST Costco delivered every element of the card's positive trigger: revenue of $95.7 billion, EPS of $6.75, and a worldwide renewal rate of 89.8%, up from 89.7%. After an early gap down to as low as $883.10, the stock reversed and closed the 24 hours after up 3.25% at $922.77, inside the card's +3% to +6% positive range and the first quarter in over a year that a Costco beat was actually rewarded, even with some analysts flagging that part of the EPS beat came from a one-off tariff refund.
What else moved the price
The card named a one-time tariff refund as a detail it could not have known in advance; reporting shows it accounted for $0.15 of the EPS beat and drew mixed analyst commentary on earnings quality, without stopping the stock from rallying on the underlying renewal-rate and comparable-sales strength the card said mattered more.
COST price from the signal through fiscal fourth quarter earnings, in the order it happened. Price Date and time 925.14 883.10 896.48 12:41 13:30 20:00 20:15 13:30 19:50 20:00 16 Sept 21 Sept 24 Sept 25 Sept After signal After fiscal fourth quarter earnings (24 Sep 2026, after the close) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Wed, 16 Sept 2026, 18:00 onsemi Investor Day could reset AI growth, margin and Synaptics targets 73.20 +5% to +9% −1.57% High −10.11% Low Details for ON ON result After the event it went to −1.57% at its highest, and later to −10.11% at its lowest, against the close price before analyst day.
The news was
On one side the 2030 model sits well above what the company is running at now: 12% to 14% annual revenue growth to nearly $11 billion, a 53% gross margin against about 40% this year, more than $3.5 billion of free cash flow and AI data-center revenue growing at least 50% a year to more than $2.5 billion. On the other, the addressable market was cut by $30 billion to $213 billion because Synaptics is excluded, that deal is not expected to close until mid-2027, and 53% is the same gross margin target set in 2023 and missed every year since.
Measured from Price at analysis Close price before analyst day Detailed view onsemi used its analyst day to publish a 2030 financial model: 12% to 14% annual revenue growth to nearly $11 billion of revenue, a 53% gross margin, a 38% operating margin and more than $3.5 billion of free cash flow, with AI data-center revenue growing from about $500 million this year to more than $2.5 billion. It also cut the market it says it addresses to $213 billion from the $243 billion it gave in June, because Synaptics is excluded until that deal closes in mid-2027, and the shares fell.
What else moved the price
The card called the day crowded and named the Federal Reserve, which was right about the clash and wrong about who won it. The decision landed at 18:00 UTC, the same minute the presentation began, and the stock held its price for the next half hour before breaking two minutes after the 2030 targets were published at 18:30. The semiconductor ETF SMH closed 0.64% higher on the day, so the afternoon belonged to management rather than to the Fed. Quarterly index expiry on 18 September, which the card also flagged, falls outside the window measured here.
ON price from the signal through analyst day, in the order it happened. Price Date and time 76.35 65.80 73.20 13:17 13:34 19:59 21:26 18:30 19:12 20:00 1 Sept 10 Sept 11 Sept 15 Sept 16 Sept 17 Sept After signal After analyst day (16 Sep 2026, 18:30 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Tue, 15 Sept 2026, 13:00 Corteva presents stand-alone targets for Vylor and New Corteva before the October 1 separation 82.54 4% to 8% over one to three trading days. −1.62% Low +3.21% High Details for CTVA CTVA result After the event it went to −1.62% at its lowest, and later to +3.21% at its highest, against the close price before investor day.
The news was
On one side the separation stopped being a plan and became a date, with a record date, a distribution date and a ticker, and Vylor guided its EBITDA margin from 27% to 30% by 2029. On the other, it guided long-term sales growth of only 3% to 4%, below what the market was looking for from the faster-growing half.
Measured from Price at analysis Close price before investor day Detailed view Corteva set out stand-alone plans for both halves of the company and fixed the split: the board approved the distribution the day before, with a record date of 24 September and Vylor trading on the NYSE as VYLR from 1 October, one share for every Corteva share held. The seed company guided to higher margins by 2029 on modest sales growth.
CTVA price from the signal through investor day, in the order it happened. Price Date and time 90.87 81.20 82.54 13:29 13:30 13:31 17:55 20:00 21 Aug 24 Aug 3 Sept 14 Sept 15 Sept After signal After investor day (15 Sep 2026, 13:00 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Wed, 9 Sept 2026, 17:00 Apple’s September 9 product event could unveil its first foldable iPhone 316.22 +3% to +6% on a launch-ready foldable, -2% to -5% on delay or weak details −2.00% Low +0.93% High Details for AAPL AAPL result After the event it went to −2.00% at its lowest, and later to +0.93% at its highest, against the close price before product event.
The news was
The foldable landed at $1,999, which is the price the market wanted. Against that, it ships on 23 October rather than with the rest of the lineup.
Measured from Price at analysis Close price before product event Detailed view Apple unveiled its first foldable iPhone, the Duo, at $1,999, alongside the iPhone 18 Pro at $1,199 and the Pro Max at $1,299. Preorders open on 16 October and it reaches 70 countries on 23 October, so the launch lands next month rather than with the rest of the lineup.
AAPL price from the signal through product event, in the order it happened. Price Date and time 330.81 309.90 316.22 15:15 17:00 18:15 18:55 20:00 2 Sept 3 Sept 8 Sept 9 Sept 10 Sept After signal After product event (9 Sep 2026, 17:00 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Wed, 26 Aug 2026, 21:00 NVIDIA reports fiscal Q2 2027 results, with Q3 guidance and Vera Rubin timing in focus 209.66 Down 3% to 6% during the first one to three sessions. −2.94% Low +9.93% High Details for NVDA NVDA price from the signal through earnings, in the order it happened. Price Date and time 230.47 203.50 209.66 08:01 13:30 19:52 20:00 20:20 20:22 13:30 13:35 17:25 20:00 21 Aug 24 Aug 26 Aug 27 Aug After signal After earnings (26 Aug 2026, 20:20 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Wed, 23 Sept 2026, 23:00 Meta unveils its next AI glasses and headset at Connect, two days after Muse sent the stock up 11% 744.10 +2% to +4% if Muse gets new usage numbers and a next-model date, -3% to -6% if the keynote is hardware only −3.24% Low +4.80% High Details for META Meta delivered essentially the full positive trigger and then some: a new, larger Muse download figure (3.4 million, up from 2.5 million), immediate model updates in place of a promised date, and a priced, dated hardware lineup, plus a genuine surprise, the Muse Charm pendant device, that the card had not modeled. The stock closed the 24 hours after up 4.90%, at $777.59, and peaked at $779.82, both above the card's own +2% to +4% positive range and within 0.75% of the 52-week high.
What else moved the price
The card named profit-taking into the unfilled 21 September gap as the main risk to the rally continuing. That gap was never tested; the new information from the keynote extended the move instead of reversing it.
META price from the signal through Connect 2026 keynote, in the order it happened. Price Date and time 779.82 720.00 744.10 19:59 20:13 13:56 20:00 23:00 09:45 13:30 19:50 20:00 21 Sept 22 Sept 23 Sept 24 Sept After signal After Connect 2026 keynote (23 Sep 2026, 23:00 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Thu, 24 Sept 2026 DRI Darden Restaurants, Inc. Darden reports first quarter results with Olive Garden facing its hardest comparison of the year 213.69 +3% to +7% if same-restaurant sales clear 3.1% and adjusted earnings clear $2.05 with the LongHorn margin holding, -4% to -8% if Olive Garden lands near 1% and the LongHorn margin narrows again −3.50% Low −0.33% High Details for DRI Darden landed almost exactly on the card's neutral case: same-restaurant sales of 3.1% to 3.2%, adjusted earnings of $2.05, and full-year guidance reaffirmed unchanged. The one real surprise was positive, LongHorn's segment margin expanded to 18.0% from 17.4%, the metric the card said was the real risk; the one real soft spot was Olive Garden, in line with the card's negative marker. The stock still fell, closing the session down about 3% from the pre-earnings close, giving back a rally built on five recent broker target raises.
What else moved the price
The company flagged cyclospora-related consumer caution and World Cup scheduling as quarter-specific headwinds to demand, factors outside anything the card modeled, while saying trends had already improved into September.
DRI price from the signal through fiscal first quarter earnings, in the order it happened. Price Date and time 216.17 198.29 213.69 20:00 17:59 20:00 11:04 13:30 14:17 20:00 18 Sept 23 Sept 24 Sept After signal After fiscal first quarter earnings (24 Sep 2026, before the open) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Wed, 30 Sept 2026, 20:30 MU Micron Technology, Inc. Micron's fiscal Q4 results are the first real test of a stock the market still prices for a crash 1065.11 +6% to +12% −3.96% Low +3.17% High Details for MU MU result After the event it went to −3.96% at its lowest, and later to +3.17% at its highest, against the close price before Fiscal Q4 2026 earnings.
The news was
The numbers were unambiguously good and the spending behind them was not. Revenue, margin, earnings and the next quarter's guide all came in above what the company had told the market to expect, and management called an 86.25% gross margin the floor for fiscal 2027 rather than the peak. Against that, first-half fiscal 2027 capital spending of about 25 billion dollars is roughly 91% of the whole of fiscal 2026 in half the time, research and development rises by more than 1 billion dollars, and a planned pay increase adds to costs. In memory, spending on that scale reads as future supply, which is the one thing a market paying about 7 times forward earnings is braced for. The tape traded both readings in a single session before settling 3.03% higher.
Measured from Price at analysis Close price before Fiscal Q4 2026 earnings Detailed view Micron beat its own guidance on every line of fiscal Q4 2026, with revenue of 54.23 billion dollars, an 87.0% gross margin and 33.42 dollars of adjusted earnings, and guided the next quarter to a record 61.5 billion dollars with the margin called a floor. The market sold it anyway on a fiscal 2027 capital plan of about 25 billion dollars in the first half alone, taking the stock to $1022.90 on the morning of 1 October before it reversed to close at $1097.39, up 3.03% on the day.
What else moved the price
Little of the move came from outside Micron. On 1 October SPY rose 0.18% and QQQ 0.31%, so the index contributed almost nothing to a 3.03% session. The semiconductor complex did move, but mostly downstream of this release rather than alongside it: SMH rose 1.45%, and the three equipment names the card had tied to the capital spending line, AMAT at 3.50%, LRCX at 3.53% and KLAC at 2.77%, were reacting to Micron's own capital plan. Press coverage of the day also noted Treasury yields retreating from their highest levels in more than twenty years, which helped the broad tape recover from early losses, but the index close of 0.18% caps how much of Micron's session that can explain. The larger prices in this window were not the earnings at all. The stock fell 11.78% from the $1023.15 signal price to $902.60 on 14 September with no Micron news found to match it, then rose 22.84% from there to the $1108.72 high on 25 September, both moves larger than the result itself produced.
MU price from the signal through Fiscal Q4 2026 earnings, in the order it happened. Price Date and time 1108.72 902.60 1065.11 20:00 20:02 13:30 14:23 19:59 20:00 9 Sept 14 Sept 25 Sept 30 Sept 1 Oct After signal After Fiscal Q4 2026 earnings (30 Sep 2026, 16:02 ET (20:02 UTC)) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Wed, 16 Sept 2026 Lennar reports third quarter results hours after a Fed decision that is priced to raise rates 78.36 +6% to +10% if gross margin holds at or above 16%, -8% to -13% if margin misses and Q4 is guided lower −5.90% Low +3.37% High Details for LEN LEN result After the event it went to −5.90% at its lowest, and later to +3.37% at its highest, against the close price before earnings.
The news was
On one side the discount finally narrowed: incentives came down to 12.0% from 12.9%, the home-sales margin improved to 15.8% from 15.6%, and the fourth quarter was guided to 22,000 to 23,000 deliveries with adjusted earnings of $1.30 to $1.65, all above the quarter just reported. On the other, new orders of 20,879 missed the guided floor and fell 9% year on year, revenue came in around $300 million light, the full-year delivery target was cut, and management put the 30-year mortgage near 7% with nearly half of visitors unable to qualify.
Measured from Price at analysis Close price before earnings Detailed view Lennar sold homes at a smaller discount and still could not sell enough of them: incentives fell to 12.0% of the price from 12.9% and the margin on home sales rose to 15.8%, but new orders of 20,879 came in below the company guidance and 9% below a year earlier. It cut its full-year delivery target to 80,000 to 81,000 homes from 82,000 to 83,000, and management declined to say the discounting had peaked.
What else moved the price
The card called the day crowded and named the Federal Reserve, and it was right about the clash and wrong about who owned the reaction. The Fed raised to 3.75% to 4.00% at 18:00 UTC on 16 September and every builder fell with Lennar that afternoon, but the session this result is judged on was the next one, and that one belonged to housing data rather than to the Fed. August housing starts at 12:30 UTC on 17 September showed single-family starts up 7.6% while total starts fell 2.6% and permits fell 2.7%, and the stock gapped straight to its high of the day at the open alongside D.R. Horton at 1.49% and PulteGroup at 1.10%. So the opening gap was the sector data as much as the print, and the fall that followed was the market reading the order book. Quarterly index expiry on 18 September, which the card also flagged, falls outside the window measured here.
LEN price from the signal through earnings, in the order it happened. Price Date and time 81.45 73.74 78.36 13:30 19:25 20:00 20:30 13:30 13:41 20:00 11 Sept 16 Sept 17 Sept After signal After earnings (16 Sep 2026, 20:30 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Tue, 22 Sept 2026 IONS Ionis Pharmaceuticals, Inc. FDA decision on Ionis zilganersen for Alexander disease is due September 22 61.33 +3% to +7% −6.11% Low −4.32% High Details for IONS The FDA approved zilganersen as ZANVASTRO on 3 September 2026, 19 days before its target date, as the first treatment for Alexander disease in children and adults. The approval lifted the stock about 1% on a day it had already fallen 6.29%, and a partner trial failure the next evening set the direction from there.
What else moved the price
The card rated 22 September clear, but the decision came on 3 September, and that day was not about the approval. IONS opened 1.48% below the prior close and was down 6.29% by the afternoon, before the FDA acted, with the biotechnology ETF XBI down only 0.60% and no company news found to explain it. The approval accounts for only the last 0.88% of the day. The larger driver came the next evening: after the close on 4 September Novartis announced that pelacarsen, partnered with Ionis, missed its primary endpoint in the Phase 3 Lp(a)HORIZON outcomes trial, removing a royalty stream in the mid-teens to low twenties percent. The stock opened 8 September 10.2% lower. It then fell from $54.21 to $44.44 between 11 and 18 September without a single disclosure I could find to explain it, and sits at $44.38 now, 25.71% below the signal price.
IONS price from the signal through FDA decision, in the order it happened. Price Date and time 64.58 44.38 61.33 19:27 19:49 19:52 20:00 20:05 21 Aug 25 Aug 26 Aug 2 Sept 3 Sept 23 Sept After signal After FDA decision (3 Sep 2026, 19:49 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Wed, 23 Sept 2026, 13:00 FDA advisory panel votes on GRAIL's Galleri multi-cancer blood test 108.52 +20% to +35% on a clearly positive vote, -25% to -40% on a negative vote −8.77% Low +16.85% High Details for GRAL The FDA advisory panel backed GRAIL's Galleri multi-cancer blood test on 23 September 2026: 10 to 0 on safety, 7 to 2 with one abstention on benefit-risk, and 6 to 4 on effectiveness. The stock was halted during the meeting, and most of the move had already come on 21 September, when the briefing documents sent it up 33.68%. It closed 24 September at $125.21, +51.70% from the signal price.
What else moved the price
The panel was not the biggest mover. The FDA briefing documents on 21 September did most of the work, taking the stock from $80.77 to $107.97 in one session. Before that GRAL drifted down with no Galleri news, to a $73.46 low on 14 September, and then rose 6.44% on 17 September on 1.53 million shares ahead of the documents. The market was little help: on 23 September, while GRAL was halted, SPY fell 0.72% and XLV 0.64%. On 24 September SPY slipped 0.08% and XLV rose 0.63%, so the +15.38% that day was the vote, not the market.
GRAL price from the signal through FDA advisory panel vote, in the order it happened. Price Date and time 126.89 73.46 108.52 18:17 20:00 11:05 12:37 13:30 19:49 20:00 25 Aug 14 Sept 22 Sept 24 Sept 25 Sept After signal After FDA advisory panel vote (23 Sep 2026, 22:17 UTC) Regular session Pre-market / After-hours Closing price Recorded after the event and not edited since. Past moves are not a forecast of future ones.
Passed Thu, 8 Oct 2026, 10:00 PepsiCo reports third-quarter results at a 52-week low, with a quarter that closed before September’s diesel spike reached its delivery trucks 128.63 +3% to +6% on a full reaffirmation with snack profit stabilising Pending — Passed Thu, 8 Oct 2026, 13:00 LOGI Logitech International S.A. Logitech unveils its largest ever range of business video devices at Logi Launch, with a supplier outage hanging over the holiday quarter 105.12 +1% to +3% if devices ship this quarter and supply is easing, -1% to -3% if they ship in 2027 or supply is not addressed Pending — Passed Fri, 9 Oct 2026 Delta reports third-quarter results with jet fuel near $4.61 a gallon against the $3.15 its guidance assumed, and its own refinery on the other side of the trade 84.94 +3% to +7% Pending — Passed Mon, 12 Oct 2026, 07:45 Stellantis unveils nine concept cars at the Paris Motor Show with its shares at a 52-week low 4.81 +1% to +4% if premieres come with prices and dates and Canada settles, -1% to -4% if concepts only or a strike is under way Pending — Passed Tue, 13 Oct 2026 UNH UnitedHealth Group Incorporated UnitedHealth reports third-quarter results with medical-cost recovery and raised full-year guidance under review 376.59 +8% to +12% on better medical costs and raised guidance Pending — Passed Tue, 13 Oct 2026, 10:45 JPMorgan reports third-quarter earnings after guiding to mid-to-high-teens growth in markets and investment-banking revenue 343.06 +3% to +5% on a beat and raise Pending — Passed Thu, 15 Oct 2026, 06:00 TSM Taiwan Semiconductor Manufacturing Company Limited TSMC reports third-quarter results after August sales surged 53% and AI demand lifted its full-year outlook 450.61 +6% to +9% on a beat and stronger forward outlook Pending — Passed Fri, 16 Oct 2026, 00:30 Tesla reveals the production Roadster at the SpaceX McGregor site, two weeks later than planned 375.30 -2% to -6% if the reveal gives no firm production start Pending — Passed Fri, 16 Oct 2026, 12:00 Apple launches pre-orders for the $1,999 iPhone Duo, its first foldable, with hinge supply capping the first year 338.98 +1% to +3% Pending — 
